| Rx0000297 |
MannKind Corporation |
09/30/2023 |
47918089190 |
Afrezza 12 Unit Inhalation Powder Metered 1 Carton |
Brand |
FDA |
07/03/2023 |
76.58 |
1352.94 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2023 |
47918087490 |
Afrezza 4 Unit Inhalation Powder Metered 1 Carton |
Brand |
FDA |
07/03/2023 |
25.53 |
450.97 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2023 |
47918088018 |
Afrezza 4 Unit; 8 Unit Inhalation Powder Metered 1 Carton |
Brand |
FDA |
07/03/2023 |
76.58 |
1352.94 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2023 |
47918090218 |
Afrezza 4 Unit; 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton |
Brand |
FDA |
07/03/2023 |
102.11 |
1803.93 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2023 |
47918087890 |
Afrezza 8 Unit Inhalation Powder Metered 1 Carton |
Brand |
FDA |
07/03/2023 |
51.05 |
901.96 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2023 |
47918089818 |
Afrezza 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton |
Brand |
FDA |
07/03/2023 |
127.64 |
2254.91 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
06/30/2023 |
73499000101 |
Wynzora Cream 0.005%/0.064%, 60g |
Brand |
FDA |
05/19/2023 |
54.08 |
1255.83 |
None |
Single Source Drug |
27000 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
03/31/2023 |
43538044060 |
Nicadan, 800-10-100, TAB, 60 EA |
Brand |
Medispan |
01/10/2023 |
28.05 |
547.54 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000382 |
Melinta Therapeutics, LLC |
03/31/2023 |
70842016010 |
MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (100mg dose) |
Brand |
FDA |
02/16/2023 |
114.00 |
2390.00 |
05/12/2031 |
Single Source Drug |
None |
1 |
Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors.
Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary. |
None |
None - see cost increase factors statement. |
None |
01/05/2018 |
The Medicines Company |
None |
1 |
None |
1544.13 |
1544.13 |
2015 |
1470.60 |
None |
None |
| Rx0000382 |
Melinta Therapeutics, LLC |
03/31/2023 |
70842012006 |
VABOMERE (meropenem/vaborbactam) is administered via intravenous injection and packaged as 6 VIAL, SINGLE-DOSE in 1 CARTON / 2 g in 1 VIAL. |
Brand |
FDA |
02/16/2023 |
62.00 |
1296.00 |
04/06/2039 |
Single Source Drug |
None |
1 |
Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors.
Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in VABOMERE as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary. |
None |
None - see cost increase factors statement. |
None |
01/05/2018 |
The Medicines Company |
None |
1 |
None |
990.00 |
990.00 |
2017 |
990.00 |
None |
None |
| Rx0000138 |
Merck Sharp & Dohme LLC |
03/31/2023 |
00006542312 |
BRIDION 10 200 mg/2 mL Vial (ML) |
Brand |
FDA |
01/06/2023 |
80.80 |
1235.00 |
01/27/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
. capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
. investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
03/31/2023 |
00006542515 |
BRIDION 10 500 mg/5 mL Vial (ML) |
Brand |
FDA |
01/06/2023 |
148.00 |
2262.00 |
01/27/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
. capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
. investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2023 |
00006412102 |
GARDASIL 9 0.5 mL Syringes 10 |
Brand |
FDA |
08/12/2023 |
187.62 |
2867.85 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
. capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
. investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2023 |
00006411903 |
GARDASIL 9 0.5 mL Vials 10 |
Brand |
FDA |
08/12/2023 |
187.62 |
2867.85 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
. capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
. investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2023 |
00006482700 |
VARIVAX 0.5 mL Vials 10 |
Brand |
FDA |
08/12/2023 |
143.32 |
1735.73 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
. capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
. investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2023 |
72495020105 |
FEMRING, RING, 0.05MG/DAY, (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE PER BOX |
Brand |
FDA |
01/01/2023 |
60.43 |
696.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
485.37 |
443.67 |
2003 |
76.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2023 |
72495020210 |
FEMRING, RING, 0.10MG/DAY, (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE PER BOX |
Brand |
FDA |
01/01/2023 |
64.39 |
742.25 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
517.23 |
472.79 |
2003 |
81.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2023 |
72495040128 |
Intrarosa, Insert, 6.5mg/1, 28 blister packs per box |
Brand |
FDA |
01/01/2023 |
14.40 |
254.42 |
03/19/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/26/2020 |
AMAG |
None |
1 |
None |
212.30 |
202.00 |
2017 |
175.00 |
None |
There was an NDC change for this product in 2021 from 64011060128 (AMAG) to 72495040128 (Milicent) |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037440101 |
Depen (Penicillamine Tabs) 250mg 1s |
Brand |
FDA |
01/03/2023 |
471.21 |
7202.76 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037480170 |
Elestrin 0.06% Gel 35g DualPack 2s |
Brand |
FDA |
01/03/2023 |
16.35 |
249.99 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
49502090230 |
EMSAM TDS Patch 12mg/day 30s |
Brand |
FDA |
01/03/2023 |
133.64 |
2042.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
49502090030 |
EMSAM TDS Patch 6mg/day 30s |
Brand |
FDA |
01/03/2023 |
133.64 |
2042.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
49502090130 |
EMSAM TDS Patch 9mg/day 30s |
Brand |
FDA |
01/03/2023 |
133.64 |
2042.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037044217 |
Felbatol 600mg/5mL Oral Suspension 32oz 1s |
Brand |
FDA |
01/03/2023 |
455.72 |
6966.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037044267 |
Felbatol 600mg/5mL Oral Suspension 8oz 1s |
Brand |
FDA |
01/03/2023 |
118.19 |
1806.59 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037043001 |
Felbatol Tabs 400mg 100s |
Brand |
FDA |
01/03/2023 |
96.16 |
1469.94 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037043101 |
Felbatol Tabs 600mg 100s |
Brand |
FDA |
01/03/2023 |
110.21 |
1684.64 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
00037682210 |
Proctofoam HC 1% 10g Foam 1s |
Generic |
FDA |
01/03/2023 |
11.53 |
176.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
03/31/2023 |
49502080693 |
YUPELRI Inhalation Solution 175mcg/3mL 30s |
Brand |
FDA |
01/03/2023 |
85.12 |
1301.13 |
10/23/2039 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |